Frequent CGM use ties to bigger A1c drops in type 2 diabetes, even across GLP-1, SGLT2, and insulin regimens. In this episode ...

USANewsGroup.com News Commentary - There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in ...

If you are wondering whether DexCom shares are priced attractively right now or if the stock still carries a premium, this article breaks down what the current market price might be implying about the ...

In terms of stakeholders revenue share in 2022, the Mobile Operators and Device Vendors segments represented more than ...

Sedentary behaviour is associated with an increased risk of cardiovascular disease and all-cause mortality in people with ...

The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out ...

Continuous glucose monitoring (CGM) is now the standard of care for people with type 1 diabetes in many countries, but its role in the management of type 2 diabetes is less well established. This is ...

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

Dexcom develops continuous glucose monitoring (CGM) devices. Diabetic patients use these to track their glucose levels in ...

CEO Robert B. Ford remains optimistic about the company's opportunity in the continuous glucose monitor (CGM) market.

DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and ...

Over the last six months, DexCom’s shares have sunk to $62.07, producing a disappointing 6.4% loss - a stark contrast to the ...